These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 27821156)

  • 1. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
    Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
    J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
    Serratrice C; Swiader L; Serratrice J
    J Med Case Rep; 2015 Jun; 9():146. PubMed ID: 26100396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
    Amato D; Patterson MA
    J Med Case Rep; 2018 Jan; 12(1):19. PubMed ID: 29373994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
    Pastores GM; Barnett NL; Kolodny EH
    Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement and substrate reduction therapy for Gaucher disease.
    Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
    Ceravolo F; Grisolia M; Sestito S; Falvo F; Moricca MT; Concolino D
    J Med Case Rep; 2017 Jan; 11(1):19. PubMed ID: 28103924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.
    Elstein D; Dweck A; Attias D; Hadas-Halpern I; Zevin S; Altarescu G; Aerts JF; van Weely S; Zimran A
    Blood; 2007 Oct; 110(7):2296-301. PubMed ID: 17609429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project.
    Giraldo P; Andrade-Campos M; Alfonso P; Irun P; Atutxa K; Acedo A; Barez A; Blanes M; Diaz-Morant V; Fernández-Galán MA; Franco R; Gil-Cortes C; Giner V; Ibañez A; Latre P; Loyola I; Luño E; Hernández-Martin R; Medrano-Engay B; Puerta J; Roig I; de la Serna J; Salamero O; Villalón L; Pocovi M
    Blood Cells Mol Dis; 2018 Feb; 68():173-179. PubMed ID: 27836529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project.
    Giraldo P; Alfonso P; Atutxa K; Fernández-Galán MA; Barez A; Franco R; Alonso D; Martin A; Latre P; Pocovi M
    Haematologica; 2009 Dec; 94(12):1771-5. PubMed ID: 19608672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
    Elstein D; Hollak C; Aerts JM; van Weely S; Maas M; Cox TM; Lachmann RH; Hrebicek M; Platt FM; Butters TD; Dwek RA; Zimran A
    J Inherit Metab Dis; 2004; 27(6):757-66. PubMed ID: 15505381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective treatment of an elderly patient with Gaucher's disease and Parkinsonism: a case report of 24 months' oral substrate reduction therapy with miglustat.
    Hughes DA; Ginsberg L; Baker R; Goodwin S; Milligan A; Richfield L; Mehta AB
    Parkinsonism Relat Disord; 2007 Aug; 13(6):365-8. PubMed ID: 17049454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Miglustat: new drug. In type 1 Gaucher's disease : a slight benefit after imiglucerase therapy.
    Prescrire Int; 2005 Oct; 14(79):168-70. PubMed ID: 16285070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
    Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A
    Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
    Canda E; Kose M; Kagnici M; Ucar SK; Sozmen EY; Coker M
    Blood Cells Mol Dis; 2018 Feb; 68():180-184. PubMed ID: 28111116
    [No Abstract]   [Full Text] [Related]  

  • 15. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
    Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
    Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
    Pastores GM; Elstein D; Hrebícek M; Zimran A
    Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study.
    Cox TM; Amato D; Hollak CE; Luzy C; Silkey M; Giorgino R; Steiner RD;
    Orphanet J Rare Dis; 2012 Dec; 7():102. PubMed ID: 23270487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination.
    Capablo JL; Franco R; de Cabezón AS; Alfonso P; Pocovi M; Giraldo P
    Epilepsia; 2007 Jul; 48(7):1406-8. PubMed ID: 17433057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Goal-oriented therapy with miglustat in Gaucher disease.
    Pastores GM; Giraldo P; Chérin P; Mehta A
    Curr Med Res Opin; 2009 Jan; 25(1):23-37. PubMed ID: 19210136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease.
    Giraldo P; Latre P; Alfonso P; Acedo A; Alonso D; Barez A; Corrales A; Franco R; Roldan V; Serrano S; Pocovi M
    Haematologica; 2006 May; 91(5):703-6. PubMed ID: 16627252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.